Anheuser-Busch InBev (NYSE: BUD) on Thursday before market open reported a rise in both revenue and profit, and raised its full-year guidance. Top line revenue exceeded Wall Street estimates, and the stock was up approximately 4.6% in pre-market trading.

online pharmacy purchase champix no prescription with best prices today in the USA

The world’s largest brewer, and makers of Bud Light hard seltzer, attributed its performance to “relentless execution, investment in our brands and accelerated digital transformation.”

online pharmacy neurontin no prescription

EBITDA for the quarter was $250 million, compared with $1.04 billion for the year-earlier period, the company reported.

AB InBev said that it expects normalized profit growth of between 10% and 12%, with revenue growth exceeding 12%. It had previously forecast normalized EBITDA growth in the range of 8% to 12%.

This is breaking news, with further analysis coming after today’s earnings report and interview with industry analysts.

online pharmacy https://www.caseymedical.com.au/wp-content/uploads/backup/2022/12/amoxil.html with best prices today in the USA
online pharmacy kamagra-oral-jelly no prescription pharmacy